WWW.BOOK.DISLIB.INFO
FREE ELECTRONIC LIBRARY - Books, dissertations, abstract
 
<< HOME
CONTACTS



Pages:     | 1 |   ...   | 20 | 21 || 23 | 24 |   ...   | 34 |

«2013 Annual Report breakthrough technologies and services focused on Dear Fellow Shareholders, addressing specific customer and market needs. Several ...»

-- [ Page 22 ] --

Goodwill and Other Intangible Assets: The Company’s intangible assets consist of (i) goodwill, which is not being amortized; (ii) indefinite lived intangibles, which consist of certain trademarks and trade names that are not subject to amortization; and (iii) amortizing intangibles, which consist of patents, trade names and trademarks, licenses, customer relationships, and purchased technologies, which are being amortized over their estimated useful lives.

The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of a two-step process. The first step is the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. The second step measures the amount of an impairment loss, and is only performed if the carrying value exceeds the fair value of the reporting unit. This annual impairment assessment is performed by the Company on the later of January 1 or the first day of each fiscal year. This same impairment test will be performed at other times during the course of the year, should an event occur which suggests that the recoverability of goodwill should be reconsidered. Nonamortizing intangibles are also subject to an annual impairment test. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized. In addition, the Company evaluates the remaining useful life of its non-amortizing intangible assets at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful lives of non-amortizing intangible assets are no longer indefinite, the assets will be tested for impairment. These intangible assets will then be amortized NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) prospectively over their estimated remaining useful life and accounted for in the same manner as other intangible assets that are subject to amortization. Recoverability of amortizing intangible assets is assessed only when events have occurred that may give rise to impairment. When a potential impairment has been identified, forecasted undiscounted net cash flows of the operations to which the asset relates are compared to the current carrying value of the long-lived assets present in that operation. If such cash flows are less than such carrying amounts, long-lived assets, including such intangibles, are written down to their respective fair values. See Note 12, below, for additional details.

Stock-Based Compensation: The Company accounts for stock-based compensation expense based on estimated grant date fair value, generally using the Black-Scholes option-pricing model. The fair value is recognized, net of estimated forfeitures, as expense in the consolidated financial statements over the requisite service period. The determination of fair value and the timing of expense using option pricing models such as the Black-Scholes model require the input of highly subjective assumptions, including the expected forfeiture rate, life of the option and the expected price volatility of the underlying stock. The Company estimates the expected forfeiture and expected life assumptions based on historical experience. In determining the Company’s expected stock price volatility assumption, the Company reviews both the historical and implied volatility of the Company’s common stock, with implied volatility based on the implied volatility of publicly traded options on the Company’s common stock. The Company has one stock-based compensation plan from which it makes grants, which is described more fully in Note 18, below.

Marketable Securities and Investments: The cost of securities sold is based on the specific identification method. If securities are classified as available for sale, the Company records these investments at their fair values with unrealized gains and losses included in accumulated other comprehensive income. Under the cost method of accounting, equity investments in private companies are carried at cost and are adjusted for otherthan-temporary declines in fair value, additional investments or distributions.

Cash and Cash Equivalents: The Company considers all highly liquid unrestricted instruments with a purchased maturity of three months or less to be cash equivalents. The carrying amount of cash equivalents approximates fair value due to the short maturities of these instruments.

Environmental Matters: The Company accrues for costs associated with the remediation of environmental pollution when it is probable that a liability has been incurred and the Company’s proportionate share of the amount can be reasonably estimated. The recorded liabilities have not been discounted.

Research and Development: Research and development costs are expensed as incurred. The fair value of acquired in-process research and development (“IPR&D”) costs are recorded at fair value as an intangible asset at the acquisition date and amortized once the product is ready for sale or expensed if abandoned.

Restructuring Charges: In recent fiscal years, the Company has undertaken a series of restructuring actions related to the alignment with the Company’s growth strategy, the impact of acquisitions, divestitures and the integration of its business units. In connection with these initiatives, the Company has recorded restructuring charges, as more fully described in Note 4, below. Generally, costs associated with an exit or disposal activity are recognized when the liability is incurred. Costs related to employee separation arrangements requiring future service beyond a specified minimum retention period are recognized over the service period. Costs related to lease terminations are recorded at the fair value of the liability based on the remaining lease rental payments, reduced by estimated sublease rentals that could be reasonably obtained for the property, at the date the Company ceases use.





Comprehensive Income: In February 2013, the FASB issued ASU 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, requiring the presentation of reclassifications out NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) of accumulated other comprehensive income on the face of the financial statements or as a separate disclosure in the notes to the financial statements. The reclassifications out of accumulated other comprehensive income and into net income were not material for the fiscal years ending December 29, 2013, December 30, 2012 and January 1, 2012. See Note 19 for additional details.

Comprehensive income is defined as net income or loss and other changes in stockholders’ equity from transactions and other events from sources other than stockholders. Comprehensive income is reflected in the consolidated statements of comprehensive income.

Derivative Instruments and Hedging: Derivatives are recorded on the consolidated balance sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting.

For a cash flow hedge, the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income and subsequently amortized into net earnings when the hedged exposure affects net earnings. Cash flow hedges related to anticipated transactions are designated and documented at the inception of each hedge by matching the terms of the contract to the underlying transaction.

The Company classifies the cash flows from hedging transactions in the same categories as the cash flows from the respective hedged items. Once established, cash flow hedges are generally recorded in other comprehensive income, unless an anticipated transaction is no longer likely to occur, and subsequently amortized into net earnings when the hedged exposure affects net earnings. Discontinued or dedesignated cash flow hedges are immediately settled with counterparties, and the related accumulated derivative gains or losses are recognized into net earnings on the consolidated financial statements. Settled cash flow hedges related to forecasted transactions that remain probable are recorded as a component of other comprehensive income and are subsequently amortized into net earnings when the hedged exposure affects net earnings. Forward contract effectiveness for cash flow hedges is calculated by comparing the fair value of the contract to the change in value of the anticipated transaction using forward rates on a monthly basis. As of December 29, 2013, the Company had no outstanding cash flow hedges, and as of December 30, 2012, the Company had two outstanding cash flow hedges with Euro denominated notional amounts of €50.0 million. The Company also has entered into foreign currency forward contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into net earnings on the consolidated financial statements.

Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the FASB and are adopted by the Company as of the specified effective dates. The Company believes that the impact of recently issued pronouncements will not have a material impact on the Company’s consolidated financial position, results of operations, and cash flows or do not apply to the Company’s operations.

Note 2: Business Combinations Acquisitions in fiscal year 2013 The Company completed the acquisition of four businesses for total consideration of $11.4 million, in cash.

As of the closing dates, the Company potentially had to pay additional contingent consideration for the four acquired businesses of up to $2.2 million, which at closing had an estimated fair value of $1.1 million. The excess of the purchase price over the fair value of each of the acquired businesses’ net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and has been allocated to goodwill, none of which is tax deductible. The Company reported the operations for these acquisitions within the results of the Company’s operations from the acquisition dates.

As of December 29, 2013, the purchase accounting allocations related to these acquisitions were preliminary.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) Acquisition in fiscal year 2012 Acquisition of Haoyuan Biotech Co., Ltd. In November 2012, the Company acquired all outstanding stock of Shanghai Haoyuan Biotech Co., Ltd. (“Haoyuan”). Haoyuan is a provider of nucleic acid-based blood screening solutions for the blood banking and clinical diagnostics markets. The Company expects this acquisition to extend the Company’s capabilities into nucleic acid blood screening, as well as deepen its position in the growing molecular clinical diagnostics market in China. The Company paid the shareholders of Haoyuan $38.0 million in cash for the stock of Haoyuan. The Company recorded a receivable of $2.7 million from the shareholders of Haoyuan as a reduction of purchase price for the settlement of certain contingencies. This receivable was collected in fiscal year 2013. As of the closing date, the Company potentially had to pay the shareholders additional contingent consideration of up to $30.0 million, which at closing had an estimated fair value of $1.9 million. The excess of the purchase price over the fair value of the acquired net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and has been allocated to goodwill, none of which is tax deductible. The Company reported the operations for this acquisition within the results of the Company’s Human Health segment from the acquisition date.

The total purchase price has been allocated to the estimated fair values of assets acquired and liabilities

assumed as follows:

–  –  –

The weighted average amortization periods of identifiable definite-lived intangible assets for core technology and trade names were 8 years.



Pages:     | 1 |   ...   | 20 | 21 || 23 | 24 |   ...   | 34 |


Similar works:

«Publikationen Herrmann-Lingen 2014 2010 Albus C, Ladwig KH, Herrmann-Lingen C. Psychokardiologie eine Übersicht praxisrelevanter Erkenntnisse und Handlungsempfehlungen zu ausgewählten HerzKreislauferkrankungen. Dtsch Med Wochenschr 2014;139:596-601. Herrmann-Lingen C, Brunner E, Hildenbrand S, Loew TH, Raupach T, Spies C, Treede RD, Vahl CF, Wenz HJ. Evaluation of medical research performance – position paper of the Association of the Scientific Medical Societies in Germany (AWMF). GMS Ger...»

«European on Health Systems and Policies TACKLING CHRONIC DISEASE IN EUROPE Strategies, interventions and challenges Reinhard Busse, Miriam Blümel, David Scheller-Kreinsen, Annette Zentner Observatory Studies Series No 20 Tackling chronic disease in Europe The European Observatory on Health Systems and Policies supports and promotes evidencebased health policy-making through comprehensive and rigorous analysis of health systems in Europe. It brings together a wide range of policy-makers,...»

«Aus der Klinik für Dermatologie, Venerologie und Allergologie Charité Centrum 12 für Innere Medizin und Dermatologie der Medizinischen Fakultät Charité Universitätsmedizin Berlin DISSERTATION Charakterisierung der Hautbarrierefunktion von Frühund Reifgeborenen innerhalb der ersten Lebensjahre unter Berücksichtigung angewandter Pflegekonzepte in der Neonatalperiode Zur Erlangung des akademischen Grades Doctor medicinae (Dr. med.) vorgelegt der Medizinischen Fakultät...»

«Struktur und Funktion von S-Layern acidophiler Bakterien und Archaeen, ihre Rolle bei der PyritOxidation sowie die Adhäsion an Oberflächen Dissertation zur Erlangung des Doktorgrades der Naturwissenschaften (Dr. rer. nat.) der Naturwissenschaftlichen Fakultät III Biologie und Vorklinische Medizin der Universität Regensburg vorgelegt von Andreas Klingl aus Deggendorf Januar 2011 Diese Arbeit wurde angeleitet von Prof. Dr. Reinhard Rachel Promotionsgesuch eingereicht am: 25.01.2011 Tag der...»

«Virginia Department of Medical Assistance Services Compiled Public Comment Submission Virginia’s §1115 Waiver Application Comment Period 12/04/15 – 01/06/16 Acknowledgements The Department of Medical Assistance Services would like to thank our community stakeholders and partners who submitted comments on the §1115 Innovation Waiver Application. We appreciate your input and find the collective responses valuable as we continue to work towards a comprehensive waiver application. All...»

«Aus der Klinik für Kardiovaskuläre Chirurgie der Medizinischen Fakultät Charité – Universitätsmedizin Berlin DISSERTATION Evaluation der Biokompatibilität von mit autologen Zellen beschichtetem xenogenen Gewebe im Tiermodell zur Erlangung des akademischen Grades Doctor medicinae (Dr. med.) vorgelegt der Medizinischen Fakultät Charité – Universitätsmedizin Berlin von Torsten Christ aus Lichtenstein Gutachter: 1.: Prof. Dr. med. P. Dohmen 2.: Prof. Dr.med. T. Volk 3.: Priv.-Doz. Dr....»

«1 Geschlechterunterschiede in der kortikalen Repräsentation der glücklichen und unglücklichen Liebeeine fMRI -Studie der medizinischen Fakultät/ der Psychiatrischen Klinik mit Psychotherapie der Friedrich-Alexander-Universität Erlangen-Nürnberg zur Erlangung des Doktorgrades Dr. med. vorgelegt von Katharina Walburga Marie Anna Veh aus Weißenburg Als Dissertation genehmigt von der medizinischen Fakultät / vom Fachbereich Psychiatrie der Friedrich-Alexander-Universität Erlangen-Nürnberg...»

«345 ORTET et al. Journal ofcorta deland Health Psychology © International Versión Clinical JS-NEO-S ISSN 1697-2600 2010, Vol. 10, Nº 2, pp. 345-357 The Spanish version of the GELOPH15: Properties of a questionnaire for the assessment of the fear of being laughed at1 Hugo Carretero-Dios2 (University of Granada, Spain), René T. Proyer (University of Zurich, Switzerland), Willibald Ruch (University of Zurich, Switzerland), and Victor J. Rubio (Universidad Autónoma de Madrid, Spain) ABSTRACT....»

«Numerische Untersuchungen zum biomechanischen Verhalten verschiedener orthodontischer Ankerimplantate Inaugural-Dissertation zur Erlangung des Doktorgrades der Hohen Medizinischen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn Eva Stahl aus Dormagen Angefertigt mit Genehmigung der Medizinischen Fakultät der Universität Bonn 1. Gutachter: Prof. Dr.rer.nat. Christoph Bourauel 2. Gutachter: PD Dr. med. Burger Tag der Mündlichen Prüfung: 22.10.2008 Aus der Poliklinik für...»

«Aus der Abteilung für Zahnerhaltung und Präventivzahnmedizin der Medizinischen Fakultät Charité – Universitätsmedizin Berlin DISSERTATION Vergleichende klinische Prüfung der Wirksamkeit vier verschiedener Bleichtherapien Zur Erlangung des akademischen Grades Doctor medicinae dentariae (Dr. med. dent.) vorgelegt der Medizinischen Fakultät Charité – Universitätsmedizin Berlin von Elke Schmidt aus Königs Wusterhausen Gutachter: 1. Prof. Dr. K.-R. Jahn 2. Prof. Dr. med. dent. S....»





 
<<  HOME   |    CONTACTS
2016 www.book.dislib.info - Free e-library - Books, dissertations, abstract

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.